E
Neonc Technologies Holdings, Inc. NTHI
$9.36 $0.647.34% NASDAQ
Recommendation
Prev Close
$8.72
Volume
61,088
Avg Vol (90D)
134,261
Market Cap
$169.82M
Dividend & Yield
--
52-Week Range
$3.20 - $25.00
P/E (TTM)
--
EPS (TTM)
-$2.66
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Insider Buys Additional US$185k In NeOnc Technologies Holdings Stock
12/2/2025 - Simply Wall St
NeOnc Technologies (Nasdaq: NTHI) Announces AI-Driven Findings Showing Ultrasound Enhances the ...
12/1/2025 - GuruFocus
NeOnc Technologies (Nasdaq: NTHI) Announces AI-Driven Findings Showing Ultrasound Enhances the Potency of an Already Effective NEO100 in Treating Primary and Metastatic Brain Tumors
12/1/2025 - Globe Newswire
Favourable Signals For NeOnc Technologies Holdings: Numerous Insiders Acquired Stock
11/15/2025 - Simply Wall St
NeOnc Technologies Secures $50M Partnership with Quazar
11/14/2025 - TipRanks Financial Blog
NeOnc Technologies Holdings Reports Third Quarter 2025 Results and Provides Operational Update
11/14/2025 - GuruFocus
NeOnc Technologies Holdings Reports Third Quarter 2025 Results and Provides Operational Update
11/14/2025 - Globe Newswire
NeOnc Technologies Completes Enrollment in Pivotal NEO100 Phase2a Trial for IDH-1 mutant Recurrent High Grade Glioma and Expects Interim Data Readout in SixMonths (Q22026)
11/13/2025 - Globe Newswire
NeOnc Technologies Reports Promising Clinical Trial Results
11/12/2025 - TipRanks Financial Blog
NeOnc Technologies Reports Updated Clinical Results
11/12/2025 - Globe Newswire
NeOnc Technologies Schedules Investor Call for Trial Updates
11/10/2025 - TipRanks Financial Blog
NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Data Updates from ...
11/7/2025 - GuruFocus
NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Data Updates from Ongoing NEO100-1 Phase 1/2a Clinical Trial and Compassionate Use Program
11/7/2025 - Globe Newswire
NeOnc Technologies Appoints Amir Heshmatpour as Chief Executive Officer to Drive Next Phase of Clinical and Corporate Growth
11/4/2025 - Globe Newswire
His Highness Sheikh Nahyan bin Zayed Al Nahyan Assumes Executive Chairmanship of NeOnc Technologies' Subsidiary, NuroMENA, Pioneering UAE-US Partnership in Brain Cancer Treatment
10/28/2025 - Globe Newswire
NeOnc Technologies' NEO100 Study: A Potential Game-Changer in Glioma Treatment?
10/27/2025 - TipRanks Financial Blog
NeOnc Technologies Announces $50M Partnership with Quazar
10/10/2025 - TipRanks Financial Blog
NeOnc Technologies' Subsidiary, NuroMENA, Signs Master Services Agreement with M42's IROS and Expands Board of Directors
10/9/2025 - Globe Newswire
NeOnc Technologies and Quazar Investment Set to Close $50 Million Strategic Partnership by October 23rd Following Final UAE Tax Approvals
10/6/2025 - Globe Newswire
NeOnc Technologies Appoints Dr. David M. Ashley, Director of The Preston Robert Tisch Brain Tumor Center at Duke, to Scientific Advisory Board
10/2/2025 - Globe Newswire
NeOnc Technologies Welcomes Dr. Alexandra M. Miller, Chief of Neuro-Oncology and Co-Director of the Brain and Spine Tumor Center at NYU Langone Health's Perlmutter Cancer Center, to Its Scientific Advisory Board
10/1/2025 - Globe Newswire
NeOnc Technologies Appoints Renowned Neuro-Oncologist Dr. Henry S. Friedman to Scientific Advisory Board
9/29/2025 - Globe Newswire
NeOnc Technologies to Showcase Progress on Addressing Brain Cancer to 63 Million TV Households on Health Uncensored with Dr. Drew on the Lifetime Network on September 25, premiering nationwide at 8:00 a.m. ET/PT
9/22/2025 - Globe Newswire
NeOnc Technologies Advances to Phase II Brain Cancer Trial
9/11/2025 - TipRanks Financial Blog
Blue Gold Appoints Quazar's Sameer Salgar to Advisory Board to Establish UAE Ties and Guide Digital Gold Strategy
9/10/2025 - Globe Newswire
Income Statement
Total Revenue (TTM)
$60.00K
EBITDA (TTM)
--
EBIT (TTM)
-$46.64M
Net Income (TTM)
-$48.88M
Balance Sheet
Total Assets (Q)
$4.08M
Total Debt (Q)
$5.08M
Total Liabilities (Q)
$15.90M
Book Value Per Share (Q)
-$0.6067
Cash Flow
Cash from Operations (TTM)
-$17.73M
Cash from Investing (TTM)
--
Cash from Financing (TTM)
$17.91M
Net Change in Cash (TTM)
$178.60K
Filings
Filing Date
Friday, November 14, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
Beginning of January (est)
Price History
Loading...
Beta
--
7-Day Total Return
59.73%
30-Day Total Return
-1.16%
60-Day Total Return
10.38%
90-Day Total Return
73.01%
Year to Date Total Return
-22.71%
1-Year Total Return
--
2-Year Total Return
--
3-Year Total Return
--
5-Year Total Return
--
52-week Low
Jul 02, 2025 - $3.20
52-week High
Mar 26, 2025 - $25.00
Valuation
Market Cap
$169.82M - Micro Cap
Enterprise Value
$173.38M
Price/Sales (TTM)
2,812.90
Price/Book (Q)
-14.37
Dividends and Shares
Shares Outstanding
19.21
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.neonc.com
Phone Number
310-663-7831
Address
23975 Park Sorrento
Calabasas, CA 91302
Country
United States
Year Founded
2005
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a... more
NASDAQ 12/03/2025 2:17PM Eastern Quotes delayed